Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Creo Medical Group's operating assets for the quarter that ended in Dec. 2025 was $62.52 Mil. Creo Medical Group's operating liabilities for the quarter that ended in Dec. 2025 was $6.69 Mil. Creo Medical Group's Total Assets for the quarter that ended in Jun. 2025 was $93.35 Mil. Therefore, Creo Medical Group's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.60.
Creo Medical Group Scaled Net Operating Assets Related Terms
Creo Medical Group Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group Scaled Net Operating Assets Chart
CMEOF vs ABT, SYK, MDT: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, Creo Medical Group's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.60 mean?
Creo Medical Group (CMEOF) has a Scaled Net Operating Assets of 0.60 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Creo Medical Group and its competitors.
Is Creo Medical Group's Scaled Net Operating Assets too high?
Creo Medical Group's current Scaled Net Operating Assets is 0.60. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Scaled Net Operating Assets compare to ABT and SYK?
Creo Medical Group's Scaled Net Operating Assets of 0.60 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Creo Medical Group and its competitors. Creo Medical Group's current Scaled Net Operating Assets is 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current Scaled Net Operating Assets of 0.60. The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current Scaled Net Operating Assets is 0.60. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Scaled Net Operating Assets is 0.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.
Key valuation signals for CMEOF:
Scaled Net Operating Assets: 0.60
GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score
Get the complete analysis for CMEOF
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
